1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
55.29 USD   +17.46%
05/26Novavax Announces Participation in Oxford University Com-COV3 Booster Trial of COVID-19 Vaccines in Adolescents Aged 12 Through 15
AQ
05/24Indian vaccine giant Serum plans African plant in global expansion
RE
05/23Novavax Files in the European Union for Expanded Conditional Marketing Authorization of COVID-19 Vaccine as a Booster in Individuals Aged 18 and Over
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

01/12/2022 | 06:00am EDT

Novavax, Inc. and SK bioscience Co. Limited announced that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a Biologics License Application (BLA) from SK bioscience for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization in individuals 18 years of age and older for the prevention of COVID-19 caused by SARS-CoV-2. Nuvaxovid™, Novavax' COVID-19 vaccine also known as NVX-CoV2373, is the first protein-based COVID-19 vaccine to be approved for commercial use in South Korea and will be manufactured and marketed in the country by SK bioscience. SK bioscience has an advance purchase agreement with the South Korean government to supply 40 million doses of Novavax' vaccine. The companies also recently announced expanded collaboration and license agreements that are expected to increase manufacturing capacity and provide SK bioscience with additional non-exclusive territories. Novavax' vaccine also recently received conditional marketing authorization (CMA) in the European Union and emergency use listing (EUL) from the World Health Organization (WHO) under the brand name Nuvaxovid. The Novavax/Serum Institute of India Pvt. Ltd. vaccine (brand name, Covovax™) recently received emergency use authorization (EUA) in India, Indonesia and the Philippines, as well as WHO EUL. Together, the WHO EULs for the vaccine from both companies reflect the potential opportunity for authorization in over 170 countries. The vaccine is also currently under review by multiple additional regulatory agencies worldwide and the company expects to receive additional worldwide authorizations in the first half of 2022. This includes the submission of its complete chemistry, manufacturing and controls (CMC) data package to the U.S. Food and Drug Administration (FDA) at the end of 2021. The company expects to submit a request for EUA for the vaccine in the U.S. after one month in accordance with guidance from the FDA regarding submission of all EUA vaccines.


© S&P Capital IQ 2022
All news about NOVAVAX, INC.
05/26Novavax Announces Participation in Oxford University Com-COV3 Booster Trial of COVID-19..
AQ
05/24Indian vaccine giant Serum plans African plant in global expansion
RE
05/23Novavax Files in the European Union for Expanded Conditional Marketing Authorization of..
AQ
05/20SECTOR UPDATE : Health Care Stocks Rebound In Final Hour of Friday Trade
MT
05/20SECTOR UPDATE : Health Care Stocks Beginning to Sputter Amid Broader Markets Slide
MT
05/20Novavax Shares Drop After BofA Securities Begins Coverage at Underperform
MT
05/20EMA Starts Evaluation of Booster Dose Usage of Novavax's COVID-19 Vaccine
MT
05/20EMA Starts Evaluating Use Of Booster Dose Of Nuvaxovid In Adults
RE
05/20BofA Securities Initiates Coverage on Novavax With Underperform Rating
MT
05/16Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan
AQ
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 4 278 M - -
Net income 2022 1 941 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 2,33x
Yield 2022 -
Capitalization 4 320 M 4 320 M -
EV / Sales 2022 0,42x
EV / Sales 2023 0,31x
Nbr of Employees 1 541
Free-Float 99,0%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 55,29 $
Average target price 154,86 $
Spread / Average Target 180%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-61.35%4 320
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478